Across TCGA pan-cancer cohorts, INTS12 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated INTS12 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher INTS12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated INTS12 expression acts as an unfavorable survival marker.
DLBC are the cancer types where INTS12 Mutation most reproducibly stratifies survival.